Skip to main content

Ginkgo Bioworks Holdings, Inc.

corporate_fare Company Profile

Ginkgo Bioworks Holdings, Inc.

DNA·NYSE·Life Sciences·CIK 0001830214

Ginkgo Bioworks Holdings, Inc. provides services to government and commercial customers, aiming to make biology easier to engineer. The company operates through two business segments: cell engineering and biosecurity. In the cell engineering segment, Ginkgo offers tools and biological research and development (R&D) services across various industries. These services support customers in medicine for developing new therapeutics and vaccines, in agriculture for advancing food system sustainability and security, in industrial biotechnology for manufacturing products with improved performance and lower environmental impact, and in government for advancing new R&D priorities of strategic importance to the United States and its allies. Traditionally, biotech R&D involves in-house labs with scientists conducting manual experiments over several years to develop products. The biosecurity segment provides services to customers focused on identifying, monitoring, preventing, mitigating, and protecting against biological threats.

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 10 items for DNA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 10 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for DNA spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Ginkgo 10-Q: Q3 Loss Narrows to $41M, $285M Liquidity Funds 12+ Months
  • Ginkgo Q3 Revenue $28M, Loss Narrows to $41M; First Autonomous Lab Sale to Novo
  • Ginkgo Posts Narrower Q3 Loss, Lands First Autonomous Lab Sale to Pharma Giant Novo
  • Ginkgo Bioworks Q2 Revenue Halves to $20M, Cash Runway Tightens as $47M Gets Locked Up
  • Ginkgo Bioworks Reports 49% Revenue Decline, Q1 Loss; $47M Cash Restricted Post-Quarter

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$170.16M
Net Income
-$312.76M
Diluted EPS
-$5.64
Op. Cash Flow
-$171.06M
Free Cash Flow
-$178.72M
Operating Income
-$315.28M
Cash & Equivalents
$167.2M
Debt / Equity
0.00×
Net Margin
-183.8%
Shares Outstanding
58.21M sh
Source: 10-K · filed 2026-02-26 · accession 0001628280-26-012346

Short Interest & Short Volume

3.85 days to cover

FINRA reported short interest of 9,490,310 shares in DNA as of the October 30, 2026 settlement, a 14.4% increase from the prior period — about 3.9 days to cover at its recent average daily volume. On November 20, 2026, 64.2% of DNA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)9,490,310 shares as of October 30, 2026
Change vs prior period▲ 14.4%
Days to cover3.85 at avg daily volume of 2,464,798
Daily short volume (FINRA facilities)64.2% of 859,781 shares on November 20, 2026
5-day average short volume56.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with D →
$7.55 +1.21% today
52-week range · as of 2026-11-09 $5.37 – $18.22
Market cap
$483.59M
Volume
2.5M (1.0× avg)
3-mo avg 2.5M
Live data · 2026-11-21 15:50 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed DNA - Latest Insights

DNA
Nov 09, 2026, 4:52 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $12.30
Real-time Price: $7.55 info
Change: -$4.75 (-39%) info
Market Cap: $483.595M info
DNA
Nov 05, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.80
Real-time Price: $7.55 info
Change: -$2.25 (-23%) info
Market Cap: $483.595M info
DNA
Nov 05, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $9.95
Real-time Price: $7.55 info
Change: -$2.40 (-24%) info
Market Cap: $483.595M info
DNA
Aug 06, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.50
Real-time Price: $7.55 info
Change: -$0.950 (-11%) info
Market Cap: $483.595M info
DNA
May 07, 2026, 4:13 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $9.05
Real-time Price: $7.55 info
Change: -$1.50 (-17%) info
Market Cap: $483.595M info
DNA
May 07, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $8.56
Real-time Price: $7.55 info
Change: -$1.01 (-12%) info
Market Cap: $483.595M info
DNA
Apr 07, 2026, 5:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.82
Real-time Price: $7.55 info
Change: +$0.730 (+11%) info
Market Cap: $483.595M info
DNA
Feb 26, 2026, 9:56 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.21
Real-time Price: $7.55 info
Change: -$0.660 (-8%) info
Market Cap: $483.595M info
DNA
Feb 26, 2026, 6:17 PM EST
Source: Reuters
Importance Score:
9
Price at Filing: $7.87
Real-time Price: $7.55 info
Change: -$0.320 (-4%) info
Market Cap: $483.595M info
DNA
Feb 26, 2026, 4:34 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $8.07
Real-time Price: $7.55 info
Change: -$0.520 (-6%) info
Market Cap: $483.595M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets